Payment overview · 2025
General Payments
$202.67
10 reported records · 8 companies
Healthcare provider profile · identity verified
Jonathan Malone Buchanan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARTHAGE, MS · NPI 1073925244
Verified facts
What the public records show
CMS Open Payments records show Jonathan Malone Buchanan, M.D. received $202.67 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.31 | 17.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.62 | 17.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $30.48 | 15.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.32 | 12.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.11 | 10.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.65 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.25 | 9.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.93 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.67 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.62 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 201 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
201 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 412 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 99 |
| Gabapentin | Gabapentin | 259 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 254 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 219 | 62 |
| Ozempic | Semaglutide | 201 | 33 |
| Metformin Hcl | Metformin Hcl | 168 | 44 |
| Omeprazole | Omeprazole | 161 | 47 |
| Potassium Chloride | Potassium Chloride | 157 | 35 |
| Losartan Potassium | Losartan Potassium | 143 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 40 |
| Furosemide | Furosemide | 133 | 41 |
| Tramadol Hcl | Tramadol Hcl | 132 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 27 |
| Alprazolam | Alprazolam | 124 | 20 |
| Famotidine | Famotidine | 120 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 117 | 33 |
| Allopurinol | Allopurinol | 113 | 28 |
| Spironolactone | Spironolactone | 112 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 23 |
| Pregabalin | Pregabalin | 109 | 18 |
| Lisinopril | Lisinopril | 101 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 22 |
| Carvedilol | Carvedilol | 85 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Linzess | Linaclotide | 77 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 23 |
| Eliquis | Apixaban | 74 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 19 |
| Montelukast Sodium | Montelukast Sodium | 72 | 20 |
| Jardiance | Empagliflozin | 67 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 15 |
| Baclofen | Baclofen | 65 | 11 |
| Sertraline Hcl | Sertraline Hcl | 62 | 12 |
| Cefdinir | Cefdinir | 59 | 53 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Promethazine Hcl | Promethazine Hcl | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 55 | 14 |
| Nabumetone | Nabumetone | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 16 |
| Mirtazapine | Mirtazapine | 50 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Glimepiride | Glimepiride | 46 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 13 |
| Trazodone Hcl | Trazodone Hcl | 42 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Celecoxib | Celecoxib | 40 | 13 |
| Meloxicam | Meloxicam | 39 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Naproxen | Naproxen | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 12 |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 19 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 13 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acitretin | Acitretin | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.67 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ARTIX MT, CAPVAXIVE, GARDASIL 9, Ozempic, QULIPTA, QUTENZA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VAXNEUVANCE, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error